Last reviewed · How we verify
Enoxaparin Injectable Solution
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood clotting by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Prevention of venous thromboembolism in surgical patients, Treatment of deep vein thrombosis and pulmonary embolism, Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction).
At a glance
| Generic name | Enoxaparin Injectable Solution |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Antithrombin III (indirect); Coagulation factors Xa and IIa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. It is used to prevent and treat venous thromboembolism and acute coronary syndromes.
Approved indications
- Prevention of venous thromboembolism in surgical patients
- Treatment of deep vein thrombosis and pulmonary embolism
- Acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction)
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated liver enzymes
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enoxaparin Injectable Solution CI brief — competitive landscape report
- Enoxaparin Injectable Solution updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI